- About us
- Clinical Trials
- News & Publications
- Business Development
SOTIO® is a biotechnology company developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit. SOTIO® is owned by the PPF Group, one of the largest investment groups in Central and Eastern Europe.
The most advanced project is proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products.
Through agreements with Cytune Pharma, NBE-Therapeutics and Lead Discovery Center, SOTIO has added more novel oncology programs to its pipeline. We collaborate together to advance these programs to the clinical development stage and towards commercialization.
SOTIO, a biotechnology company owned by the PPF Group, today announced the enrollment of the first patient to a Phase II study testing DCVAC/OvCa in combination with standard of care chemotherapy ...
Responsible for successful conduct of assigned clinical
projects. Serves as the Project Lead for key business
development opportunities. Responsible for establishing
working relationships with client project teams to ensure client
satisfaction and operational excellence...
The Head Global Regulatory Affairs will be responsible
for forming the regulatory strategy of SOTIO and leading
all aspects of SOTIO’s regulatory authority interactions
on a global level. She/he will have leadership and management
experience with Phase 3 into clinical development plans.
Primarily contribute to the development and overseeing
medical responsibilities in early-stage immune-oncology
programs which could be in pre-clinical as well as early
clinical stage. Providing medical support in the overall Sotio
development program as needed...